Denosumab Wins, But Could Stall At Second-Line
This article was originally published in The Pink Sheet Daily
Executive Summary
Analysts debate chances for Amgen’s would-be osteoporosis blockbuster without a marketing partner.
You may also be interested in...
Blocking Cathepsin K: Merck Wins Where Novartis Lost
Better specificity gives bone drug odanacatib success in Phase IIb.
Blocking Cathepsin K: Merck Wins Where Novartis Lost
Better specificity gives bone drug odanacatib success in Phase IIb.
Amgen’s Positive Denosumab Pivotal Trial Reduces Overhangs For Firm
Big biotech needs the potential $2.4 billion analysts estimate the bone-building drug could bring by 2016.